Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

Tiffany A. Traina, MD
Published: Friday, Feb 16, 2018



Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

In July 2017, the FDA approved neratinib for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin). The approval followed a 12-4 recommendation from the Oncologic Drugs Advisory Committee, stemming from the results of the ExteNET trial.

Traina says that neratinib is in a unique position because so much has evolved in the treatment of patients with early stage HER2-positive disease in the past year. The use of pertuzumab (Perjeta) is more widespread with an approval for use in the neoadjuvant setting in combination with trastuzumab. Data from the APHINITY trial showed that 1 year of adjuvant trastuzumab and pertuzumab was associated with improved survival outcomes.

These data makes the integration of neratinib challenging, Traina explains. Early trials with neratinib did not include patients who had prior exposure to pertuzumab, making neratinib’s role in the sequencing of agents unclear.


Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

In July 2017, the FDA approved neratinib for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin). The approval followed a 12-4 recommendation from the Oncologic Drugs Advisory Committee, stemming from the results of the ExteNET trial.

Traina says that neratinib is in a unique position because so much has evolved in the treatment of patients with early stage HER2-positive disease in the past year. The use of pertuzumab (Perjeta) is more widespread with an approval for use in the neoadjuvant setting in combination with trastuzumab. Data from the APHINITY trial showed that 1 year of adjuvant trastuzumab and pertuzumab was associated with improved survival outcomes.

These data makes the integration of neratinib challenging, Traina explains. Early trials with neratinib did not include patients who had prior exposure to pertuzumab, making neratinib’s role in the sequencing of agents unclear.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x